The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
Medpage Today on MSN2mon
Benralizumab Led to Histologic Responses in Eosinophilic EsophagitisMore patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with ...
Medpage Today on MSN3d
FDA OKs New Option for Rare Immune-Mediated VasculitisThe FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback